Last reviewed · How we verify
Endotoxin
At a glance
| Generic name | Endotoxin |
|---|---|
| Also known as | LPS, Lipopolysaccharide, Reference Endotoxin, CCRE, CCRE Lot 94332B1 |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Non-Standardized Food Allergenic Extract [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Bronchial Segmental Endotoxin Instillation in Humans (PHASE2)
- Inflammatory Challenge in Human Aggression. (PHASE2)
- Study of the Effect of Innate on the Inflammatory Response to Endotoxin
- Humidity Asthma Interventions for Low Socioeconomic Status Children (NA)
- Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use (PHASE2)
- Evaluation of the Outcome of Fecal Microbiota Transplantation (PHASE1, PHASE2)
- OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study
- Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endotoxin CI brief — competitive landscape report
- Endotoxin updates RSS · CI watch RSS
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) portfolio CI